HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial
TUCSON, Ariz., Aug. 09, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing (NGS) in a clinical trial conducted by the Worldwide Innovative Networking Consortium (WIN) investigating a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC).